

Highlights

The Action's 4th Grant Period (GP) started beginning of May 2016 and will end in December 2016. An extension of four additional months have been requested. We will inform you about the final decision taken by the COST Office.

Find below a summary of the last EUPancreas activities. Keep an eye on our website for further updates.

WG3: Training School on GENOMIC MEDICINE. May 3-7, Portoroz (Slovenia). Chair: Vita Dolzan. The training school covered a wide range of topics related to genomic medicine. Emphasis was put on the identification of predictive and prognostic biomarkers and novel molecular targets for tailored therapeutic interventions, specially focusing on rare cancers including pancreatic cancer. In addition, a Satellite workshop "In vitro and in vivo models for development of novel diagnostic and therapeutic approaches" was held. The COST Action supported 4 EUPancreas trainees and 2 trainers. Have a look at the abstract book at eupancreas.com/training

WG1: European Epidemiologists meeting/Panc4 consortium meeting. June 22-23, Milan (Italy). Chair: Núria Malats/Carlo La Vecchia. Very informative and stimulating meetings were held. WG1 members met on the first day to discuss about research undertaken in Europe on pancreatic cancer. On the following day the meeting continued jointly with the Panc4 consortium, starting with sessions dedicated to microbiome and pancreatic cancer risk. The afternoon session highlighted updates of ongoing projects on pancreatic cancer in the epidemiological research field. More information is available at eupancreas.com

WG3 meeting and MC meeting during the 48th Annual EPC meeting. July 6-9, Liverpool (UK). Chair: Stephan Hahn/Núria Malats. Members of WG3 meeting met July 7th to share information regarding ongoing activities and future prospects, with particular reference regarding the new onset diabetes and cysts tumours projects. We were thereafter informed that, unfortunately, the H2020 proposal on diabetes (DIAMOND project) was not selected for funding.

The MC meeting was held on the following day. The meeting's minutes (see eupancreas.com) contain more information on the themes discussed.

At the same time, members of Pancreatic Cancer Europe (PCE) met to discuss about future activities and new work streams to be endorsed by PCE.

WG1 & WG4: The PancreOS/ENCR meeting took place on September 22 in Ispra (Italy). Representatives from pancreatic cancer registries (PancreOS, HPSG, etc.) and population-based cancer registries (JCR/ENCR, EUROCARE, REDECAN) met to reach a consensus regarding, working protocols and the next steps to be taken to implement the PancreOS registry.

Forthcoming event (see more details at eupancreas.com)

WG4: European Health Forum Gastein (EHFG). September 28 to 30, Gastein (Austria). EHFG is the most important health-related event in the EU and a meeting point for experts from different fields within the health system. A 2-hour EUPancreas session dedicated to the burden of pancreatic cancer in Europe is planned. The COST Action will support the attendance of some EUPancreas members.

EUPancreas joins at present **245 European pancreatic cancer researchers**. Twitter: @Pancreas has now 199 followers!

Early Career Investigators (ECIs):

❖ **7th STSM call: Five new STMs were awarded.** See list of awardees at eupancreas.com/stsm

Thus far, the COST Action EUPancreas has supported 27 STSMs.

Upcoming scientific Events:

EUPancreas members will be participating in several new events. Information will be provided at eupancreas.com

- ❑ **15 to 19 October:** UEG week. Vienna, Austria
- ❑ **28 to 29 October:** EFISD - Pancreatic cancer: Where are we now? & Where are we going?" Cluj-Napoca, Romania
- ❑ **31 October to 1 November:** UICC World Cancer Congress. Paris, France
- ❑ **11 to 12 November:** Quality & Innovation in pancreatic disorders. Rome, Italy
- ❑ **13 to 16 November:** Canceromatics III. Tumor heterogeneity. Madrid, Spain
- ❑ **17 to 18 November:** HBP SurG Meeting 2016. Lyon, France.

New pancreatic cancer-related studies:

Publications acknowledging the "COST Action BM1204 EU-Pancreas"

- 📄 Kleeff, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016 Apr 21;2:16022. doi: 10.1038/nrdp.2016.22.
- 📄 Lucas, et al. Global Trends in Pancreatic Cancer Mortality From 1980 Through 2013 and Predictions for 2017. Clin Gastroenterol Hepatol. 2016 Jun 3. pii: S1542-3565(16)30269-5.

Other publications:

- 📄 Kleef, et al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J C Cancer 2016. [Epub ahead of print]
- 📄 Sousa, et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature. 2016 Aug 10. [Epub ahead of print]
- 📄 Rizzato, et al. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Carcinogenesis. 2016 Aug 5. [Epub ahead of print]
- 📄 Sandhu, et al. The genomic landscape of pancreatic and periampullary adenocarcinoma. Cancer Res. 2016 Aug 3. pii: canres.0658.2016. [Epub ahead of print]
- 📄 Zhou, et al. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer. Oncotarget. 2016 Jul 28. [Epub ahead of print]

Universita di Ljubljana

artemida
Advanced Regional Transition of
Excellent Research Innovation
for Digital Aging

Center of Excellence
in Translational
Medicine
EUROPEAN
COMMISSION
Centre of Excellence
for Translational
Medicine



PANCREATIC CANCER EUROPE
The European Multi-Stakeholder Platform on Pancreatic Cancer

